Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour
Over the past three decades, the outcome of Ewing sarcoma family tumor (ESFT) patients who are nonmetastatic at presentation has improved considerably. The prognosis of patients with metastatic disease at the time of diagnosis and recurrence after therapy remains dismal. Drug-resistant disease a...
Main Authors: | Alfredo Pinto, Paul Dickman, David Parham |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1155/2011/856190 |
Similar Items
-
IDH Mutation Analysis in Ewing Sarcoma Family Tumors
by: Ki Yong Na, et al.
Published: (2015-05-01) -
Ewing’s sarcoma: an uncommon breast tumor
by: Sawsen Meddeb, et al.
Published: (2014-10-01) -
The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors
by: Bibby, Michael C., et al.
Published: (2009) -
Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors
by: David Stahl, et al.
Published: (2019-12-01) -
Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of Tumors
by: Mario Valdes, et al.
Published: (2017-05-01)